Engineered on the structure of humanized IgG4, emicizumab mimics the function of activated FVIII to restore the FVIII binding to factor IX (FIX) and factor X (FX), which is missing in Hemophilia A patients [168,169]. The gene discussed is F8; the disease is hemophilia A.